Le Lézard
Classified in: Health
Subjects: SVY, TRI

Winner of Fresenius Kabi's Clinical Nutrition Research Grant Latin America to Begin Study on Omega-3 Fatty Acids


BAD HOMBURG, Germany, November 27, 2018 /PRNewswire/ --

Besting more than 50 research study applications, medical researcher Dr. Aurora Serralde Zúńiga's entry on the study of omega-3 fatty acids in hospital patients requiring parenteral nutrition with intestinal failure-associated complications won the first-ever Parenteral Nutrition Research Grant Latin America.

To view the Multimedia News Release, please click: https://www.multivu.com/players/Spanish/8451051-ganadora-del-subsidio-fresenius-kabi/

Dr. Serralde Zúńiga, a Doctor in Medical Sciences and clinical researcher from Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, received the coveted EUR 100,000* grant during the awarding ceremony at FELANPE Congress in Guadalajara, Mexico on September 24. This grant will enable Dr. Serralde and her research team to investigate the effects of parenteral lipid emulsions with and without omega-3 fatty acids on oxidative stress and metabolic endotoxemia in hospitalized patients with type II intestinal failure.

"Parenteral nutrition is a core pillar of day-to-day patient care," said Dr. Serralde Zúńiga. "The grant allows medical research institutions like ours to continue our research in this field. This greatly benefits not only our patients today, but also in preventing, reducing or reversing intestinal failure-associated complications in the future."

Global healthcare company, Fresenius Kabi, launched the Parenteral Nutrition Research Grant Latin America in early 2018 to support research dedicated to improving the care of hospitalized adult patients in Latin America, of whom 74 percent are moderately or severely malnourished.[1]

"This is the first time a global company is investing in a research grant in Latin America," said Parenteral Nutrition Research Grant Committee Chair Dr. Isabel Correia. "It is with great honor to present this grant to Dr. Serralde Zúńiga and her institute. We hope that this has inspired researchers to continue presenting and developing projects that will improve the future of Latin America."

The results of Dr. Serralde Zúńiga and her team's research study will be presented at the FELANPE Congress in 2020. Updates on their research and more information on the grant will be posted on unitedforclinicalnutrition.com.

*Euro amount or equivalent in local currency

About Fresenius Kabi 

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.

With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

For more information, please visit http://www.fresenius-kabi.com, or email [email protected]

References 

  1. Papapietro Vallejo K, Méndez Martínez C, Matos Adames AA et al. Current Clinical Nutrition Practices in Critically Ill Patients in Latin America: A Multinational Observational Study. Crit Care 2017; 21 (1), 227. DOI: 10.1186/s13054-017-1805-z

Media Relations Contact 
Isabel Cochrane
+49(0)69-40-12-54-353
[email protected]

     (Photo: https://mma.prnewswire.com/media/788675/Fresenius_Kabi.jpg )

Video: 
     https://www.multivu.com/players/Spanish/8451051-ganadora-del-subsidio-fresenius-kabi/

SOURCE Fresenius Kabi


These press releases may also interest you

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...



News published on and distributed by: